AstraZeneca is selling its nearly 30-acre U.S. headquarters campus in Fairfax, but not necessarily moving, according to a News Journal report.
The newspaper said sources familiar with the offering said he company wants to sell the campus and lease it back from the new owner.
Spokesperson Abigail Bozrath said the company is considering all of its options, including redeveloping the site. “In order to fully explore this [redevelopment] possibility, AstraZeneca will be soliciting bids from real estate developers in the coming months and that requires us putting the site on the market for sale,” she said.
JLL, the Chicago real estate company that handles all AstraZeneca’s sales and acquisitions, is listing the property, according to a spokeswoman for the Chicago realtor. In May, AstraZeneca announced it might leave the Fairfax campus but pledged it would remain in Delaware.
AstraZeneca has about 2,100 workers in Fairfax and Newark.